Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
MNOHOPOČETNÝ MYELÓM – Novinky z kongresu
27 ledna, 2021 8:38 pmMnohopočetný myelóm (MM) je veľmi heterogénne ochorenie, či už klinicky, biologicky alebo geneticky. Toto ochorenie však patrí v súčasnosti medzi hematologické...
PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS
27 ledna, 2021 8:38 pmAuthor(s): Abhishek Mangaonkar, Terra Lasho, Christy Finke, Naseema Gangat, et al. Abstract: PF501 Session topic: 10. Myelodysplastic syndromes...
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
27 ledna, 2021 8:38 pmAuthor(s): Paolo Strati, Guillermo Garcia-Manero, Tapan Kadia, Gautam Borthakur, et al. Abstract: PS1251 Session topic: 10. Myelodysplastic syndromes...
DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION
27 ledna, 2021 8:38 pmAuthor(s): Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, Cristina Calderon-Cabrera, et al. Abstract: PF496 Session topic: 10. Myelodysplastic...
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
27 ledna, 2021 8:38 pmAuthor(s): Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, Jorge Arbelbide, et al. Abstract: PS1259 Session topic: 10. Myelodysplastic syndromes...
MYELODYSPLASTICKÝ SYNDROM – VÝBĚR Z EDUKAČNÍCH SDĚLENÍ A POSTERŮ
27 ledna, 2021 8:38 pmPráce publikované formou edukačních sdělení 1. FACING THE CHALLENGE: NOVEL TREATMENT OPTIONS FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES Nové léčebné...
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
27 ledna, 2021 8:38 pmAuthor(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et. al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin...
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
27 ledna, 2021 8:38 pmAuthor(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical...
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma...
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
27 ledna, 2021 8:38 pmAuthor(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et. al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin...